Mucus hypersecretion in respiratory disease. Chair's introduction.

Novartis Found Symp

Department of Anatomy, University of California San Francisco, 94143, USA.

Published: May 2003

Download full-text PDF

Source

Publication Analysis

Top Keywords

mucus hypersecretion
4
hypersecretion respiratory
4
respiratory disease
4
disease chair's
4
chair's introduction
4
mucus
1
respiratory
1
disease
1
chair's
1
introduction
1

Similar Publications

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by chronic mucus hypersecretion (CMH) that exacerbates airway obstruction and accelerates disease progression. Effective airway clearance techniques are essential to improve respiratory function and reduce exacerbations. Temporary Positive Expiratory Pressure (T-PEP) is a novel airway clearance device that has shown promise in managing COPD.

View Article and Find Full Text PDF

Inula japonica Thunb. and its active compounds ameliorate airway inflammation by suppressing JAK-STAT signaling.

Biomed Pharmacother

January 2025

KM Convergence Research Division, Korea Institute of Oriental Medicine (KIOM), 1672 Yuseong-daero Yuseong-gu, Daejeon 34054, Republic of Korea. Electronic address:

Asthma, a chronic inflammatory disease, remains a global health challenge due to its complex pathophysiology and the limited treatment efficacy. This study explored the effect of Inula japonica Thunb. water extract (IJW) on asthma and its protective mechanisms.

View Article and Find Full Text PDF

Introduction: Acute exacerbations of COPD (AECOPD) often involve mucus hypersecretion. Thus, management of sputum retention is critical. However, the use of airway clearance techniques (ACTs) in people with AECOPD across different healthcare settings and factors influencing their selection remain unclear.

View Article and Find Full Text PDF

Mucus hypersecretion is a trait of chronic obstructive pulmonary disease (COPD) associated with poorer outcomes. As it may be present before airway obstruction, its early treatment may have a preventive role. This narrative review of the literature presents the role of mucus dysfunction in COPD, its pathophysiology, and the rationale for the use of N-acetylcysteine (NAC).

View Article and Find Full Text PDF

Targeting PGAM5 attenuates airway inflammation in asthma by inhibiting HMGB1 release in bronchial epithelium.

Free Radic Biol Med

January 2025

Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. Electronic address:

Article Synopsis
  • Previous studies linked high HMGB1 levels to the development of steroid-insensitive asthma caused by toluene diisocyanate (TDI), highlighting mitochondrial dysfunction in bronchial epithelia.
  • This study aims to determine if PGAM5, a mitochondrial protein, influences HMGB1 release in TDI-induced asthma by comparing its levels in asthma patients and healthy individuals and conducting various animal and in vitro experiments.
  • Findings showed that inhibiting PGAM5 reduced airway inflammation and HMGB1 release in TDI-exposed mice, illustrating a potential regulatory mechanism involving mitochondrial apoptosis-related processes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!